KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2025)

Vertex Pharmaceuticals has reported Long-Term Investments over the past 6 years, most recently at $5.7 billion for Q4 2025.

  • Quarterly results put Long-Term Investments at $5.7 billion for Q4 2025, up 11.83% from a year ago — trailing twelve months through Dec 2025 was $5.7 billion (up 11.83% YoY), and the annual figure for FY2025 was $5.7 billion, up 11.83%.
  • Long-Term Investments for Q4 2025 was $5.7 billion at Vertex Pharmaceuticals, roughly flat from $5.7 billion in the prior quarter.
  • Over the last five years, Long-Term Investments for VRTX hit a ceiling of $5.7 billion in Q3 2025 and a floor of $112.2 million in Q4 2022.
  • Median Long-Term Investments over the past 4 years was $4.4 billion (2024), compared with a mean of $3.7 billion.
  • Biggest five-year swings in Long-Term Investments: soared 2126.2% in 2023 and later grew 11.83% in 2025.
  • Vertex Pharmaceuticals' Long-Term Investments stood at $112.2 million in 2022, then soared by 2126.2% to $2.5 billion in 2023, then skyrocketed by 104.5% to $5.1 billion in 2024, then grew by 11.83% to $5.7 billion in 2025.
  • The last three reported values for Long-Term Investments were $5.7 billion (Q4 2025), $5.7 billion (Q3 2025), and $5.6 billion (Q2 2025) per Business Quant data.